Enliven Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Enliven Therapeutics (NASDAQ: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, has announced its participation in three major upcoming investor conferences in May and June 2025:

• TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET
• Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET
• Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET

All presentations will be in fireside chat format and will be webcast live through the company's investor relations website, with recordings available for 90 days after each event.

News Market Reaction

-2.21%

1 alert

-2.21% News Effect

On the day this news was published, ELVN declined 2.21%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences:

TD Cowen's 6^th Annual Oncology Innovation Summit: Insights from ASCO & EHA
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 1:00 p.m. ET

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET

Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, June 10, 2025
Time: 4:00 p.m. ET

The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 90 days following the conclusion of the live event.

About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-upcoming-investor-conferences-302463238.html

SOURCE Enliven Therapeutics, Inc.

FAQ

When is Enliven Therapeutics (ELVN) presenting at the Goldman Sachs Healthcare Conference in 2025?

Enliven Therapeutics will present at the Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 4:00 p.m. ET.

How can I watch Enliven Therapeutics' (ELVN) investor conference presentations in 2025?

The presentations can be accessed through live webcasts on Enliven's investor relations website at https://ir.enliventherapeutics.com/. Recordings will be available for 90 days after each event.

What type of company is Enliven Therapeutics (ELVN)?

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics.

Which investor conferences is Enliven Therapeutics (ELVN) attending in May-June 2025?

Enliven is attending TD Cowen's Oncology Innovation Summit (May 27), Jefferies Global Healthcare Conference (June 4), and Goldman Sachs Annual Global Healthcare Conference (June 10).